Galimedix, Inc. | WebDisclosure

Basculer en Français

9478	Companies
185492	Keywords
117871	Articles
99349	Press releases

Home
Companies
Galimedix, Inc.

PRESS RELEASE

published on 12/23/2024 at 17:30, 11 months 12 days ago

Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD
Galimedix Therapeutics initiates Phase 2 study with GAL-101 eye drops for dry AMD, aiming to slow geographic atrophy growth. Trial led by world-leading retina experts and funded by Théa Open Innovation

Galimedix Therapeutics Phase 2 Study GAL-101 Dry AMD Geographic Atrophy
BRIEF

published on 12/05/2024 at 13:33, 1 year ago

Galimedix Therapeutics lance une étude de phase 1 avec le GAL-101 oral

Étude De Phase 1 La Maladie D'Alzheimer GAL-101 Galimedix Thérapeutique DMLA Sèche
BRIEF

published on 12/05/2024 at 13:33, 1 year ago

Galimedix Therapeutics Initiates Phase 1 Study with Oral GAL-101

Alzheimer's Disease Galimedix Therapeutics GAL-101 Dry AMD Phase 1 Study
PRESS RELEASE

published on 12/05/2024 at 13:28, 1 year ago

Galimedix Therapeutics initiates Phase 1 study with oral small molecule, GAL-101, an amyloid beta (Aβ) aggregation modulator
Galimedix Therapeutics initiates Phase 1 study with oral small molecule GAL-101, targeting neurodegenerative diseases. Study focuses on safety, tolerability, and pharmacokinetics for Alzheimer's, dry AMD, and glaucoma treatments

Galimedix Therapeutics Neurodegenerative Diseases GAL-101 Alzheimer's Phase 1 Study
BRIEF

published on 06/10/2024 at 14:05, 1 year 5 months ago

Galimedix Therapeutics réunit son conseil consultatif scientifique pour l'étude de phase 2 du GAL-101

Étude Clinique De Phase 2 Conseil Consultatif Scientifique GAL-101 Galimedix Thérapeutique DMLA Sèche
BRIEF

published on 06/10/2024 at 14:05, 1 year 5 months ago

Galimedix Therapeutics Assembles Scientific Advisory Board for Phase 2 Study of GAL-101

Scientific Advisory Board Galimedix Therapeutics GAL-101 Phase 2 Clinical Study Dry AMD
PRESS RELEASE

published on 06/10/2024 at 14:00, 1 year 5 months ago

Galimedix Therapeutics establishes Scientific Advisory Board of renowned retina experts as company prepares to enter Phase 2 clinical study with GAL-101
Galimedix Therapeutics forms Scientific Advisory Board of retina experts to guide Phase 2 study with GAL-101 eye drops for dry AMD, addressing unmet medical need

Scientific Advisory Board Galimedix Therapeutics Phase 2 Study Dry AMD Retina Experts
BRIEF

published on 03/08/2024 at 10:05, 1 year 8 months ago

Galimedix Therapeutics dévoile des données prometteuses sur le traitement de la maladie d'Alzheimer à l'occasion de l'AD/PD™ 2024

Développement Clinique GAL-201 La Maladie D'Alzheimer Effets Neuroprotecteurs Fonction Cognitive
BRIEF

published on 03/08/2024 at 10:05, 1 year 8 months ago

Galimedix Therapeutics Unveils Promising Data on Alzheimer’s Treatment at AD/PD™ 2024

Clinical Development GAL-201 Alzheimer’s Disease Neuroprotective Effects Cognitive Function
PRESS RELEASE

published on 03/08/2024 at 10:00, 1 year 8 months ago

Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024
Galimedix Therapeutics presents new scientific data at AD/PD(TM) 2024, showing neuroprotective effects of GAL-201 for Alzheimer’s disease treatment, targeting misfolded Aβ monomers to prevent toxic aggregation

Alzheimer's Disease Galimedix Therapeutics Neuroprotective Effects Scientific Data AD/PD 2024

Accesswire

Published on 12/05/2025 at 16:00, 41 minutes ago

SMX Didn't Change Its Story; The World Finally Connected the Dots
Published on 12/05/2025 at 15:45, 56 minutes ago

Critical Elements announce la clôture d'un placement privé de 7,0 $ million ca par voie de prise ferme
Published on 12/05/2025 at 15:45, 56 minutes ago

Critical Elements Announces Closing of C$7.0 Million Bought Deal Life Private Placement
Published on 12/05/2025 at 15:35, 1 hour 6 minutes ago

XCF Global Moves to Double SAF Production with New Rise Reno Expansion
Published on 12/05/2025 at 15:25, 1 hour 16 minutes ago

Usha Resources Provides Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 16:25, 16 minutes ago

4YFN26 Awards: Meet the Top 20 startups building the future
Published on 12/05/2025 at 16:10, 31 minutes ago

Reorganization of the Eckert & Ziegler Executive Board
Published on 12/05/2025 at 16:00, 41 minutes ago

EQS-Adhoc: TIN INN Holding AG implements financing strategy
Published on 12/05/2025 at 16:00, 41 minutes ago

EQS-Adhoc: Amundi Physical Metals plc: Release of the Half-Year Financial Report as of September 30, 2025
Published on 12/05/2025 at 16:00, 41 minutes ago

Amundi Physical Metals plc: Communiqué de Mise à Disposition du Rapport Financier Semestriel au 30 septembre 2025

Les Echos

Published on 12/05/2025 at 15:10, 1 hour 30 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 1 hour 30 minutes ago

Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 2 hours 43 minutes ago

RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE
Published on 12/05/2025 at 08:45, 7 hours 56 minutes ago

Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 7 hours 56 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry

View all LES ECHOS COMFI WIRE